Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
07:26:08 EDT Fri 19 Apr 2024
Enter Symbol
or Name
USA
CA



Q:BNTX - BIONTECH SE SPON ADS EACH REP 1 ORD SHS - http://www.biontech.de
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
BNTX - Q4.485.34·85.774.686.17    125.83  85.212906:35:58Apr 0715 min RT 2¢

Recent Trades - All 0 today
Time ETExPriceChangeVolume
06:35:58Q85.37-0.801
06:23:59Q85.35-0.82376
06:10:36Q85.22-0.956
05:59:09Q85.35-0.824
05:59:09Q85.35-0.824
05:59:09Q85.35-0.828
05:59:09Q85.35-0.824
05:59:09Q85.35-0.824
05:10:12Q85.22-0.952
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-07 14:00U:BNTXNews ReleaseThree-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer
2024-03-20 06:15U:BNTXNews ReleaseBioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
2024-03-20 06:00U:BNTXNews ReleaseBioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer
2024-03-11 07:45U:BNTXNews ReleaseBioNTech to Present Clinical Data Updates for Personalized mRNA-based and Targeted Oncology Candidates at AACR 2024
2024-03-07 06:45U:BNTXNews ReleaseBioNTech Announces Planned Retirement of Sean Marett
2024-03-06 06:45U:BNTXNews ReleaseBioNTech to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 20, 2024
2024-02-17 10:30U:BNTXNews ReleaseROSEN, LEADING INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important Deadline in Securities Class Action - BNTX
2024-02-08 05:45U:BNTXNews ReleaseBioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs ‚  
2024-02-08 05:45U:BNTXNews ReleaseBioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs ‚   ‚  
2024-01-31 06:45U:BNTXNews ReleaseBioNTech and DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325/DB-1305
2024-01-22 11:04U:BNTXNews ReleaseROSEN, GLOBAL INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important Deadline in Securities Class Action - BNTX
2024-01-22 06:45U:BNTXNews ReleaseBioNTech and DualityBio Initiate Pivotal Phase 3 Trial Of Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Metastatic Breast Cancer
2024-01-21 09:04U:BNTXNews ReleaseROSEN, TOP RANKED GLOBAL COUNSEL, Encourages BioNTech SE Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - BNTX
2024-01-20 10:05U:BNTXNews ReleaseROSEN, GLOBAL INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important Deadline in Securities Class Action - BNTX
2024-01-19 15:06U:BNTXNews ReleaseROSEN, TOP RANKED GLOBAL COUNSEL, Encourages BioNTech SE Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - BNTX
2024-01-18 16:05U:BNTXNews ReleaseROSEN, NATIONAL INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important Deadline in Securities Class Action - BNTX
2024-01-16 15:15U:BNTXNews ReleaseSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioNTech SE of Class Action Lawsuit and Upcoming Deadlines - BNTX
2024-01-09 06:45U:BNTXNews ReleaseBioNTech Outlines 2024 Strategic Priorities at the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-21 08:00U:BNTXNews ReleaseBioNTech and DualityBio Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Endometrial Cancer
2023-12-18 13:15U:BNTXNews ReleaseBioNTech Achieves Milestone at mRNA-based Vaccine Manufacturing Site in Rwanda